

# Corrigendum

## Corrigendum to 'The pentadecapeptide [Ser<sup>1</sup>]histogranin impairs passive avoidance learning in mice' [Eur. J. Pharmacol. 283 (1995) 251–254] <sup>☆</sup>

Tangui Maurice <sup>a,\*</sup>, Alain Privat <sup>a</sup>, Simon Lemaire <sup>b,1</sup>

<sup>a</sup> I.N.S.E.R.M. U. 336, Ecole Nationale Supérieure de Chimie, Montpellier, France

<sup>b</sup> Department of Pharmacology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada

Received 10 April 1995; revised 3 July 1995; accepted 7 July 1995

### Abstract

The peptides, histogranin and [Ser<sup>1</sup>]histogranin, were recently shown to modulate NMDA receptor function. In the present study, the effects of intracerebroventricular (i.c.v.) administration of [Ser<sup>1</sup>]histogranin and of the histogranin receptor antagonist, histogranin-(1–10), were examined on step-down type passive avoidance learning in mice. [Ser<sup>1</sup>]Histogranin (30–60 nmol) impaired retention, after post-training administration, but not when it was administered just prior to the retention assay. Histogranin-(1–10) (60 nmol) facilitated learning during training, without affecting retention. Co-administration of histogranin-(1–10) with [Ser<sup>1</sup>]histogranin (60 nmol each) led to a significant prevention of [Ser<sup>1</sup>]histogranin-induced learning impairment. These results indicate that [Ser<sup>1</sup>]histogranin impairs passive avoidance learning according to the pattern of NMDA receptor antagonists and involving specific histogranin sites.

**Keywords:** Histogranin; NMDA receptor; Passive avoidance; Learning; Memory; (Mouse)

In the above-mentioned Short communication, Fig. 1 on page 253 presents the correct results but in a way that does not correspond with the legend. The correct Fig. 1 is reproduced on the right.

### The Authors

<sup>☆</sup> SSDI of original article: 0014-2999(95)00413-0

\* Corresponding author. I.N.S.E.R.M. U. 336, Ecole Nationale Supérieure de Chimie, 8, rue de l'Ecole Normale, 34053 Montpellier Cedex 1, France. Tel. (+33) 67 14 43 34, fax (+33) 67 54 06 10.

<sup>1</sup> Dr. S. Lemaire is spending a sabbatical year at I.N.S.E.R.M. U. 336, Montpellier, France.




Fig. 1. Effect of [Ser<sup>1</sup>]histogranin and histogranin-(1–10) during retention in the step-down passive avoidance test in mice. (A) Peptides were administered 10 min after the first training session. (B) The peptide was administered 30 min before retention. Columns represent the median latency of the number of animals indicated within each column. Interquartile range are indicated between brackets. Veh: vehicle. \*\*  $P < 0.01$  vs. the vehicle-treated group; +  $P < 0.05$  vs. the [Ser<sup>1</sup>]histogranin (60 nmol)-treated group; Dunn's test.